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Abstract 
Insulin receptor substrate 2 (IRS2) belongs to the 
insulin receptor substrate protein family and was 
initially discovered as an alternative route for 
signaling mediated by the insulin receptor. 
Currently, IRS2 has been well-established to 
mediate mitogenic and antiapoptotic signaling from 
several important cellular receptors. In the last years, 
many studies have indicated that IRS2 participates in 
the regulation of important biological processes 
involved in cancer phenotype, including cell 
proliferation, clonogenicity, metabolism and 
survival. The present review contains data on IRS2 
DNA/RNA, protein encoded and function. 
Keywords: IRS2; mitogenic signaling; 
antiapoptotic signaling 
Identity 
Other names: IRS-2, 4PS 
HGNC (Hugo): IRS2 
Location : 13q34 
DNA/RNA 
Description 
IRS2 was discovered as an alternative route from 
signaling mediated by the insulin receptor in Irs1 
knockout mice (Patti, et al. 1995). The entire IRS2 
gene is approximately 33.8 Kb (start: 109752698 and 
end: 109786568 bp; orientation: Minus strand) and 
contains 2 exons. The IRS2 cDNA contains 7 Kb. 
Protein 
Description 
IRS2 belongs to the insulin receptor substrate (IRS) 
protein family, which is characterized by the 
presence of a pleckstrin homology (PH) domain and 
a phosphotyrosine binding (PTB) domain (Figure 1) 
in their protein structure. The PH domain contributes 
to protein-protein binding and facilitates the 
recruitment of IRS proteins by cell membrane 
receptors.  
 Figure 1. Schematic structure of IRS2.  The pleckstrin homology (PH) domain (purple), phosphotyrosine binding (PTB) 
domain (green) and kinase regulatory loop binding domain (KRLB) are illustrated in the Figure. Amino acid (aa) positions are 
indicated.
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 Figure 2. Intracellular localization of IRS2 protein in the SET2 cell line.  Confocal analysis of SET2 (leukemia) cell line 
displaying IRS2 (red) and DAPI (blue) staining; MERGE shows the overlapped images. Scale bar: 5μm, as indicated. Note the 
predominant cytoplasm localization of IRS2. Anti-IRS2 (sc-1555) was from Santa Cruz Biotechnology and DAPI (P-36931) was 
from Life Technologies (Carlsbad, CA, USA). Personal data. 
 
The PTB domain contains multiple tyrosine sites for 
phosphorylation and is activated by cell receptors. 
Differently to other IRS family members, IRS2 has 
a kinase regulatory loop binding domain (KRLB) 
that contributes to the recruitment to cellular 
receptor (Mardilovich, et al. 2009a). 
Expression 
Ubiquitous. 
Localisation 
IRS2 protein is predominantly found in the 
cytoplasm (Figure 2). 
Function 
IRS2 is a 180 kDa adapter protein described in 1995 
as being equivalent to the 4PS protein previously 
identified as a substrate associated with the IL4 
receptor in myeloid cells (Patti, et al. 1995). IRS2 
mediates mitogenic and antiapoptotic signaling from 
insulin receptor (INSR), insulin-like growth factor 1 
(IGF1R), erythropoietin receptor (EPOR), 
thrombopoietin receptor (MPL), vascular 
endothelial growth factor receptor VEGFR (KDR), 
leptin LEP, growth hormone (GH), interleukins and 
IFNα/ IFNB1/IFNG, playing an important role in the 
response to stimuli for cytokines and growth factors, 
influencing the proliferation and survival of  
normal and cancer cells (Argetsinger, et al. 1996; 
Dearth, et al. 2007; Gibson, et al. 2007; Johnston, et 
al. 1995; Platanias, et al. 1996; Sun, et al. 1995; 
Uddin, et al. 1995; Verdier, et al. 1997; White, et al. 
1994; Yenush, et al. 1997). In addition, stimulation 
of the insulin receptor is known to result in IRS2 
association with the p85 subunit of PI3K and GRB2, 
activating proteins involved in the PI3K/AKT/ 
MTOR and MAPK pathways, respectively (Patti, et 
al. 1995; Velloso, et al. 2006)  
 
 
(canonical pathway).  
IRS2 also activates signaling pathways through other 
mechanisms (non-canonical pathways).  
For instance, angiotensin II stimulates the rapid 
phosphorylation of JAK2 tyrosine residues, 
increasing its catalytic activity and JAK2 - IRS2 
association (Folli, et al. 1997; Saad, et al. 1996; 
Saad, et al. 1995).  
The IRS2 - JAK2 association has also been described 
in rat left ventricular cells after stimulation with 
angiotensin (Velloso, et al. 2006; Velloso, et al. 
1996), and in rat liver after stimulation with leptin 
(Carvalheira, et al. 2003). Similarly, the mutant form 
of JAK2 (JAK2V617F), which is constitutively 
activated, leads to enhanced interaction between 
JAK2 and IRS2 in myeloid cells (de Melo Campos, 
et al. 2016). The main signaling pathways stimulated 
by IRS2 are shown in Figure 3. 
Homology 
The N-terminus of IRS2 shares high homology with 
that of the other members of the IRS protein family. 
IRS2 also has a high homology among different 
species (Table 1). 
Mutations 
Recurrent mutations in the IRS2 gene are rare, and 
88 substitution missense, 2 substitution nonsense, 38 
substitution synonymous, 1 insertion inframe, 3 
insertion frameshift, 4 deletions inframe and 3 
deletion frameshift mutations are reported in 
COSMIC (Catalogue of somatic mutations in cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic). 
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 Figure 3. IRS2 signaling pathway.  IRS2 is recruited by its PH/PTB domains and phosphorylated in tyrosine residues by 
upstream tyrosine kinase receptors (e.g. insulin receptor [IR], insulin-like growth factor receptor [IGF1R]). Tyrosine 
phosphorylation of IRS2 triggers PI3K/AKT/mTOR and MAPK signaling activation (canonical pathway), regulating many 
biological processes, including cell proliferation, protein synthesis, survival and gene expression in specific human tissues. IRS2 
is also activated by cytokine and hormone receptors (e.g. IL4, leptin, angiotensin), which additionally induce JAK2 stimulation 
and IRS2/JAK2 interaction, leading to STAT, PI3K/AKT/mTOR and MAPK signaling activation in rat and mouse tissues. 
Abbreviations: P, phosphorylation; PY, tyrosine phosphorylation. Figure was produced using Servier Medical Art 
(http://www.servier.com/Powerpoint-image-bank). 
 
% Identity for: 
Homo sapiens 
IRS2 
Symbol Protein DNA 
vs. P. troglodytes IRS2 96.9 97.7 
vs. M. mulatta IRS2 97.4 95.9 
vs. C. lupus IRS2 88.8 87.4 
vs. B. taurus IRS2 85.0 84.8 
vs. M. musculus Irs2 84.7 80.8 
vs. R. norvegicus Irs2 85.7 81.5 
vs. G. gallus IRS2 73.7 74.4 
vs. X. tropicalis LOC100498409 59.4 57.1 
vs. D. rerio Irs2 60.7 61.7 
vs. D. rerio zgc:56306 58.9 56.5 
Table 1. Comparative identity of human IRS2 with other 
species (Source: http://www.ncbi.nlm.nih.gov/homologene) 
Implicated in 
Breast cancer 
Jackson and colleagues (Jackson, et al. 1998) 
observed that IRS2 is widely expressed in breast 
cancer cell lines and primary breast cancer cells. In 
breast cancer patients, membrane localization of 
IRS-2 was associated with reduced overall survival 
by multivariate analysis (Clark, et al. 2011). In breast 
cancer cell lines, high IRS2 expression was 
correlated with high breast tumor invasiveness 
(Porter, et al. 2013), and with increased survival and 
cell invasion under hypoxia conditions 
(Mardilovich, et al. 2009b). Breast cancer IRS2-
depleted cells, using specific anti-sense constructs, 
presented reduced IGF1-mediated cell motility and 
lower anchorage independent growth (Jackson, et al. 
2001). In agreement, others studies demonstrated 
that IRS2 activation was required for IGF1-induced 
cell motility of the human breast cell lines MCF-7 
(Ibrahim, et al. 2008; Zhang, et al. 2004) and T47D-
YA(Byron, et al. 2006). Nagle and colleagues 
(Nagle, et al. 2004), showed that mammary tumor 
cells from IRS2 knockout mice were less invasive 
and presented more prominent apoptotic response to 
growth factor deprivation compared to wild type 
mammary tumor cells. Using breast cancer cell lines, 
Morelli and colleagues (Morelli, et al. 2003) and Cui 
and colleagues (Cui, et al. 2003) also observed that 
IRS2 could be a target of estrogen and progesterone 
receptors, respectively. Cui and colleagues (Cui, et 
al. 2006) demonstrated that EGF signaling was also 
involved in IRS2 induction/activation at the mRNA 
and protein levels via c-JUN/AP-1 stimulation, 
establishing cross-talk between IGF1R and EGFR 
signaling. Furthermore, the authors demonstrated in 
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their study that IRS2 silencing reduced EGF-induced 
invasion and migration in the mammary 
adenocarcinoma cell line MDA-MB-468 (Cui, et al. 
2006). Using the nontumorigenic mammary 
epithelial cell line MCF-10A and transgenic mice 
overexpressing human IRS2 by MMTV promoter, 
Death and colleagues (Dearth, et al. 2006) 
demonstrated the potential of malignant 
transformation of mammary cells by in vitro and in 
vivo IRS2 overexpression. Wu and colleagues (Wu, 
et al. 2010) observed that IRS2 silencing impaired 
breast cancer cell proliferation. In addition, they 
described that IGF1 induced nuclear translocation of 
IRS2 and NFKB, and promoted intranuclear 
association between IRS2 and NFKB in MCF-7 and 
BT-20 breast cancer cells, establishing a cross-talk 
between IGF1R and NFKB signaling. Slattery and 
colleagues (Slattery, et al. 2007), using a cohort of 
1664 patients with breast cancer (1089 non-Hispanic 
white and 575 Hispanic) and 2054 controls (1328 
non-Hispanic white and 726 Hispanic), found no 
association between IRS2 G1057D (rs1805097) 
polymorphism and breast cancer development. In 
contrast, Feigelson and colleagues (Feigelson, et al. 
2008) observed an association between IRS2 
polymorphisms rs4773082 (640 patients and 650 
controls), rs2289046 (552 patients and 589 controls) 
and rs754204 (642 patients and 655 controls) and 
breast cancer development. 
Colorectal cancer 
Slattery and colleagues (Slattery, et al. 2004), using 
a cohort of 1001 patients with colon cancer and 1167 
controls, and 766 patients with rectal cancer and 983 
controls,  reported that IRS2 G1057D (rs1805097) 
heterozygote GD genotype significantly reduced the 
risk of colon, though not rectal, cancer. In contrast, 
Yukseloglu and colleagues (Yukseloglu, et al. 2014), 
observed no association between IRS2 G1057D 
(rs1805097) polymorphism and risk for disease in a 
group of 161 patients with colorectal cancer and 197 
controls. Gunter and colleagues (Gunter, et al. 2007) 
observed no association of IRS2 polymorphisms 
rs2241745 (754 patients and 765 controls) and 
rs2289046 (744 patients and 758 controls) with 
advanced colorectal adenoma. IRS2 (rs2289046) GG 
genotype compared with AA plus AG genotypes was 
found to have a protective factor for colorectal 
cancer risk in normal weight subjects (Karimi, et al. 
2013). Day and colleagues (Day, et al. 2013) 
described that IRS2 mRNA and protein levels were 
positively correlated with progression from normal 
through adenoma to carcinoma in colorectal cancer, 
and that deregulated IRS2 expression activated the 
PI3K/AKT pathway and increased cell adhesion. 
Using FISH analysis, Huang and colleagues (Huang, 
et al. 2015) demonstrated that IRS2 amplification 
was a recurrent event and that IRS2 levels modulated 
the sensibility of colorectal cancer cell lines to the 
dual IGF-1R/IR inhibitor BMS-754807. In addition, 
the authors, using public available SNP array data on 
tumors, observed that the frequency of IRS2 copy 
number gain (648 samples evaluated from four 
datasets) is higher in colorectal cancer compared to 
other tumor types (Huang, et al. 2015). 
Pancreatic cancer 
In the rat pancreas RINm5F cell line, Irs2, but not 
Irs1, phosphorylation was associated with IGF1 
stimulated DNA synthesis (Zhang, et al. 1998). 
Kornmann and colleagues (Kornmann, et al. 1998) 
reported that IRS2 mRNA and protein were 
expressed in human pancreatic cancer cell lines 
(ASPC-1 and COLO-357), and highly expressed in 
primary pancreatic cancer samples compared with 
normal pancreatic samples. IGF1 and IGF2 
enhanced cell growth, stimulated IRS2 tyrosine 
phosphorylation and IRS2/PI3K association in 
ASPC-1 and COLO-357 cells (Kornmann, et al. 
1998). In AsPC-1 cell line, IGF1R/IRS2 axis 
controlled the VEGF transcription, indicating that 
this axis is an important mediator for tumor 
angiogenesis (Neid, et al. 2004). 
Neuroblastoma 
In SH-SY5Y, a human neuroblastoma cell line 
lacking IRS1, IGF1 stimulation leads to IGF1R 
activation and IRS2 phosphorylation, and activates 
PI3K and MAPK signaling (Kim, et al. 1998; Kim, 
et al. 2004). IRS2 also protects SH-EP and SH-
SY5Y neuroblastoma cell lines from glucose-
induced apoptosis by activation of PI3K/AKT and 
MAPK signaling (Kim, et al. 2009; Stohr, et al. 
2011). 
Hepatocellular carcinoma 
Boissan and colleagues (Boissan, et al. 2005) 
reported an overexpression of IRS2 in murine 
models of hepatocarcinogenesis. IRS2 mRNA and 
protein were found to be overexpressed in human 
hepatoma cell lines and primary human 
hepatocellular carcinoma specimens (Boissan, et al. 
2005; Cantarini, et al. 2006). Of note, inhibition of 
IRS2 by siRNA resulted in increased apoptosis in the 
hepatocellular carcinoma Hep3B cells. In the human 
hepatoma SMMC-7721 cell line, IRS2 silencing 
suppressed  aflatoxin B1-induced PI3K/AKT and 
MAPK activation and cell migration (Ma, et al. 
2012). Rashad and colleagues (Rashad, et al. 2014) 
observed, in 334 patients and 426 controls, that the 
D allele and the DD genotype of IRS2 G1057D 
(rs1805097) polymorphism were significantly 
associated with hepatocellular carcinoma risk. 
Hematological malignancies 
IRS2 expression was found to be downregulated in 
myelodysplastic syndrome patients compared with 
healthy donors (Machado-Neto, et al. 2012). 
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Increased IRS2 expression and phosphorylation was 
observed during erythroid, granulocytic and 
megakaryocytic differentiation in establish leukemia 
cell line models (Machado-Neto, et al. 2012). IRS2 
was found to be constitutively associated with JAK2 
in the JAK2 V617F-mutated HEL cells, but not in the 
JAK2 wild type U937 cells (de Melo Campos, et al. 
2016). In HEL cells, though not in U937 cells, IRS2 
silencing reduced cell viability and increased 
apoptosis; these effects were enhanced when 
combined with ruxolitinib, a selective JAK1/2 
inhibitor. In addition, CD34+ cells from JAK2V617F-
mutated myeloproliferative neoplasm patients 
presented increased IRS2 mRNA levels (de Melo 
Campos, et al. 2016). Savage and colleagues 
(Savage, et al. 2015) described IRS2 mutations 
(S594W and H1328R) in three out of 22 chronic 
myeloid leukemia patients with tyrosine kinase 
inhibitors resistance. Expression of each of the two 
of the IRS2 mutations in Ba/F3 cells demonstrated 
transformation capacity in the absence of IL3 
(Savage, et al. 2015). When co-expressed in Ba/F3 
cells with BCR-ABL1, these IRS2 mutants 
conferred varying degrees of reduced sensitivity to 
imatinib in vitro (Savage, et al. 2015). 
Glioblastoma 
In a study focused on PI3K/AKT-related gene 
expression analysis in glioblastoma involving 103 
patients, the IRS2 gene was amplified and 
overexpressed in 2 cases and IRS2 was also highly 
expressed in six cases with no demonstrated 
amplification (Knobbe, et al. 2003). Xu and 
colleagues (Xu, et al. 2011) identified IRS2 as a 
target of MicroRNA-153 and suggested that 
MicroRNA-153 suppressed PI3K/AKT signaling 
through IRS2 inhibition in the DBTRG-05MG 
human glioblastoma cell line. 
Prostate cancer 
Szabolcs and colleagues (Szabolcs, et al. 2009) 
reported a high expression of IRS2 in prostate cancer 
cell lines and in primary human prostate cancer 
samples, in which IRS2 was also correlated with 
MYC expression in prostate tumor samples. Ibuki et 
al. (Ibuki, et al. 2014) demonstrated an elevated 
IRS2 expression by immunohistochemistry in 
prostate cancer biopsies when compared to normal 
specimens. The in vitro treatment of LNCaP human 
prostate cancer cells with NT157, a IRS1/2 inhibitor, 
resulted in increased apoptosis and decreased cell 
proliferation (Ibuki, et al. 2014). Huang and 
colleagues (Huang, et al. 2012) observed that IRS2 
rs7986346 polymorphism was associated with 
disease progression and impaired survival in prostate 
cancer patients treated with androgen-deprivation. 
Thyroid cancer 
In the FRTL-5 rat thyroid cell line, the "RET/PTC3 
rearrangement" (inv(10)(q11q11) with NCOA4/ 
RET rearrangement), a constitutively activated 
tyrosine kinase receptor that is frequent in papillary 
thyroid cancer, induces IRS2 upregulation, and 
enhances IRS2/PI3K interaction and AKT activation 
(Miyagi, et al. 2004).  
Akker and colleagues (Akker, et al. 2014) observed 
no association between IRS2 G1057D (rs1805097) 
polymorphism and differentiated thyroid cancer 
development in a cohort of 93 differentiated thyroid 
cancer patients and 111 healthy controls. 
Mesothelioma 
IRS2 was found to be highly expressed in pleural 
mesothelioma samples and associated with cell 
motility in the H2461 cell line (Hoang, et al. 2004). 
Clear cell renal cell carcinoma 
Using semi-quantitative PCR, Al-Sarraf and 
colleagues (Al-Sarraf, et al. 2007) investigated IRS1, 
IRS2 and IRS5 mRNA expression in a cohort of 10 
patients with clear cell renal carcinoma, comparing 
normal adjacent tissue with the respective tumor 
tissue for the analysis, and found an upregulation of 
IRS2 and IRS5 mRNA in tumor samples (Al-Sarraf, 
et al. 2007). 
Endometrial cancer 
Cayan and colleagues (Cayan, et al. 2010) reported 
that IRS2 G1057D (rs1805097) polymorphism was 
associated with the development of endometrial 
cancer in a cohort of 44 patients with colon cancer 
and 101 controls. 
Malignant peripheral nerve sheath 
tumor 
High expression of IRS2 was observed in malignant 
peripheral nerve sheath tumor compared to 
neurofibromas (Shaw, et al. 2012).  
IRS2 expression was also associated with reduced 
survival in malignant peripheral nerve sheath tumors 
using univariate analysis (Shaw, et al. 2012). 
Bladder cancer 
Using cDNA microarray analysis, Zekri and 
colleagues (Zekri, et al. 2015) found IRS2 
upregulation among the genes differently expressed 
identified in bladder cancer. 
Lung cancer 
Park and colleagues (Park, et al. 2015) identified 
IRS2 as a MIR146A (MicroRNA-146a) target and 
suggested that MicroRNA-146a might suppress lung 
cancer progression by IRS2 inhibition. 
Melanoma 
In the MDA-MB-435 melanoma cell line, IRS2 
signaling was identified as a key mediator of 
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invasion promoted by α6β4 (Shaw 2001). In A375 
human melanoma cells, the in vitro treatment with 
NT157, a IRS1/2 inhibitor, led to growth 
suppression of melanoma cells by degradation of 
IRS1 and IRS2 (Reuveni, et al. 2013). Moreover, 
NT157 strongly inhibited the development of lung 
metastases of melanoma cells in mouse models 
(Reuveni et al, 2013). 
Esophageal squamous cell 
carcinoma 
Liu and colleagues (Liu, et al. 2015) identified IRS2 
as a target of MicroRNA-146a and suggested that 
MicroRNA-146a suppressed esophageal squamous 
cell carcinoma growth through inhibition of IRS2. 
Corroborating these findings, in the MicroRNA-
146a-expressing EC109 esophageal squamous cell 
carcinoma cell line, IRS2 recovery experiments 
increased cell growth. 
Gastric cancer 
Yamashita et al. (Yamashita, et al. 2006) described 
that IRS2 was methylation-silenced in gastric cancer 
specimens. Zhao and colleagues (Zhao, et al. 2012), 
reported that IRS2 G1057D (rs1805097) 
polymorphism was associated with increased 
susceptibility for gastric cancer in a cohort of 197 
patients with gastric cancer and 156 age- and sex-
matched controls. 
Oral squamous cell carcinoma 
Gao and colleagues (Gao, et al. 2014) described that 
IRS2 expression was negatively associated with 
histological differentiation of oral squamous cell 
carcinoma. In addition, IRS2 inhibition reduces cell 
proliferation, clonogenicity, cell cycle progression 
and PI3K/AKT activation in the human oral 
squamous cell carcinoma Tca-8113 cell line (Gao, et 
al. 2014). 
To be noted 
Homozygous absence of the Irs2 gene results in  type 
II diabetes and causes female infertility in mice 
(Burks, et al. 2000; Withers, et al. 1998). In view of 
the importance of IRS proteins for cancer 
development and progression, a great effort has been 
made in an attempt to develop or identify compounds 
capable of inhibiting signaling mediated by IRS 
proteins.  
In this sense, a unique subfamily of IGF1R signaling 
inhibitors (NT compounds) has been developed 
(Reuveni, et al. 2013). NT157, the most 
characterized NT compound, binds to IGF1R and 
induces a conformational change, leading to the 
dissociation of IRS1/2 from the receptor and IRS1/2 
degradation by the proteasome. NT157 was found to 
lead to long-lasting IGF1R inhibition, apoptosis, and 
present a potent antitumor effects in melanoma cells 
but not in normal melanocytes (Flashner-Abramson, 
et al. 2015; Reuveni, et al. 2013), osteosarcoma cells 
(Garofalo, et al. 2015), prostate adenocarcinoma 
cells (Ibuki, et al. 2014) and colorectal cancer cells 
(Sanchez-Lopez, et al. 2015). 
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